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Abstract: Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related mortality.
Molecular heterogeneity and absence of biomarkers for patient allocation to the best therapeutic
option contribute to poor prognosis of advanced stages. Aberrant microRNA (miRNA) expression
is associated with HCC development and progression and influences drug resistance. Therefore,
miRNAs have been assayed as putative biomarkers and therapeutic targets. miRNA-based therapeutic
approaches demonstrated safety profiles and antitumor efficacy in HCC animal models; nevertheless,
caution should be used when transferring preclinical findings to the clinics, due to possible molecular
inconsistency between animal models and the heterogeneous pattern of the human disease. In this
context, models with defined genetic and molecular backgrounds might help to identify novel
therapeutic options for specific HCC subgroups. In this review, we describe rodent models of HCC,
emphasizing their representativeness with the human pathology and their usefulness as preclinical
tools for assessing miRNA-based therapeutic strategies.
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1. MicroRNAs in HCC
MicroRNA (miRNA) profiles are highly informative for tumor classification and prognosis [1,2].
In line, the aberrant expression of miRNAs represents a hallmark of human hepatocellular carcinoma
(HCC); miRNAs signatures associated with increased HCC risk, neoplastic development, advanced
stages, and vascular invasion, were identified in human HCC, and some of them were confirmed
in rodent models and tested as therapeutic targets [3–8] (Figure 1). From a mechanistic perspective,
functional studies have demonstrated the active involvement of specific miRNAs in the regulation
of key pathways driving hepatocarcinogenesis, through the direct targeting of crucial oncogenes or
tumor-suppressor genes [3,9–14]. Besides a restricted panel of informative miRNAs shared by different
cohorts, a remarkable inconsistency can be observed across independent studies. This inconsistency
may be ascribed to the heterogeneous prevalence of etiologies, environmental and genetic factors, and
technical and analytical reasons. The molecular heterogeneity of HCC indeed still represents a critical
factor. A lack of biomarkers classifying HCC subgroups still limits our ability to allocate patients
to the best therapeutic option. In this perspective, identifying common molecular traits shared by
specific HCC subgroups and animal models might help to deepen molecular knowledge, favoring the
discovery of novel diagnostic and therapeutic approaches in molecularly defined contexts. Due to the
putative roles of miRNAs as molecular biomarkers (both tissue and circulating) as well as therapeutic
targets or therapeutic molecules, this class of RNAs deserves attention as a useful tool at multiple levels.
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Figure 1. miRNA deregulated in human and rodent human hepatocellular carcinomas (HCCs) and
miRNA-based approaches in preclinical models. Top panel depicts miRNA involved in human
hepatocarcinogenesis from early development to advanced stages. Downregulated miRNAs are in
green; upregulated miRNAs are in red. Bottom panel depicts experimental animal models of HCC
and successful miRNA treatments reducing tumor burden. miRNA mimics treatments are in green;
anti-miRNA (AM) treatments are in red [3–9,12,15–27].
2. Animal Models and HCC Research
More than 80% of human HCCs arise in a field of chronic liver disease resulting from viral hepatitis,
alcohol abuse, metabolic syndrome, exposure to carcinogenic agents, and genetic diseases such as
Wilson’s disease or hemochromatosis. Different etiologies, together with different ethnicities, contribute
to the high HCC heterogeneity. Since molecular inter-tumor and intra-tumor heterogeneity is a matter
of fact in HCC [28], identifying subclasses with predictable prognosis and response to treatments is one
of the major challenges in the clinical management of this disease. The development of animal models
that recapitulate in vivo the multistep natural history of HCCs might help in understanding the causes,
as well as provide the rationale for testing treatments. The “ideal” animal model should mimic human
HCC natural history. However, no model is “ideal” for all HCC research purposes, and spontaneous
models of tumorigenesis are rare. Because of the genetic similarities between rodents and humans, the
breeding capacity, and the short lifespan, rodents are widely used for cancer research. A wide range
of models is currently available to study HCC development and therapeutic treatments, including
chemically induced, transgenic, or knockout mice; xenograft mice; and dietary-induced models, such
as the choline-deficient diet. In addition, combinations of different models have also been used. Beside
mice and rats, zebrafish (Danio rerio) also deserve attention due to a series of characteristics that will be
briefly described. Since there is no single dominant molecular driver underlying all HCCs, specific
models should be chosen according to their representativity of specific subtypes of HCCs. Genomic
and transcriptomic studies classify HCC based on molecular pathway activation. Comparison of gene
expression between each animal model and human HCC subgroups may help to choose the ideal
model for specific aims. Here, we review some of the most representative HCC animal models selected
on the basis of the following:
- The extent of representativeness and the relevance of miRNA deregulation in human HCC;
- The translational relevance of miRNA-based therapeutic intervention in rodent models.
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3. miRNAs Knockout and Transgenic Mice
The development of genetically engineered mouse (GEM) models greatly contributed to the
advancement of knowledge of pathogenic mechanisms sustaining human diseases, including cancer.
The great advantage of GEM is that genetic manipulations can be introduced systematically,
in a specific organ, but also at defined time points during development, growth, and aging.
An exhaustive description of conditional and inducible expression systems has been reviewed
by He and coworkers [29]. GEM models also provide an optimal background for preclinical studies
testing molecularly based treatments. miRNA-based knockout (KO) or transgenic (TG) models will be
hereafter briefly described.
4. KO Mouse Models
4.1. Dicer1 KO Mouse Model
To investigate the consequences of miRNA disruption in liver physiology, Dicer1 conditional
knockout mice were established and showed initial preservation of liver function, followed by the
development of progressive liver dysfunctions leading to prominent steatosis, lipid, and glucose
metabolism impairment, increased hepatocyte proliferation, and, finally, onset of HCC [30,31].
These studies reported the downregulation of the hepatospecific miR-122 that accounts for 70%
of all expressed miRNAs in normal liver, which role in cholesterol biosynthesis and lipid metabolism is
well established [32,33]. Interestingly, despite liver repopulation by Dicer positive cells at 12-month
after birth, two-third of Alb-Cre; Dicer (fl/fl) animals displayed liver tumors exhibiting decreased levels of
Dicer1 and lack of miR-122 expression with respect to non-neoplastic surrounding tissue, demonstrating
the loss of dicer as a driver event in hepatocarcinogenesis [30]. In line, the downregulation of miRNA
machinery components (Dicer1 and p68) is a frequent event in HCC and it is associated with decreased
tumor-free survival [34].
4.2. miR-122 KO Mouse Model
Several lines of evidence highlight the importance of miR-122 in liver biology and disease,
as suggested by its downregulation in most of HCC tissues and its peculiar role in noncanonical
regulation of hepatitis C virus (HCV) life cycle, as well as by the modulation of genes involved in
the maintenance of the adult liver phenotype [3,32,35]. In this scenario, germline and liver-specific
conditional miR-122-KO mice were developed in order to investigate the consequences of its genetic
loss [36,37]. Both miR-122-KO and liver-specific KO (LKO) mice developed microsteatosis and liver
inflammation, characterized by increased lipid droplets and infiltrating cells secreting inflammatory
cytokines (IL-6 and TNF-α), that progressed to steatohepatitis, fibrosis and spontaneous HCC. Notably,
an enrichment of transcripts bearing a miR-122 complementary binding site in their 3’UTR was detected
in LKO mice and ingenuity pathway analysis (IPA) revealed the altered expression of genes belonging
to triglyceride biosynthesis, as well as oncogenes, commonly associated with malignant transformation,
such as insulin-like growth factor 2 (Igf2), beta catenin (Ctnnb1), Kirsten rat sarcoma viral oncogene
homolog (Ras), epithelial cell adhesion molecule (Epcam), and avian myelocytomatosis virus oncogene
cellular homolog (c-Myc). In addition, a signature of genes specifically deregulated in miR-122-KO
and LKO mice was able to stratify human tumor samples into high or low miR-122 expression
groups, suggesting these preclinical models as representative of the human pathology, mimicking key
features of cancer progression in a background of fatty liver disease [36]. Similarly, the reactivation of
embryo-specific genes and imprinted miRNA clusters was reported following adeno-associated virus
(AAV)-mediated miR-122 transient disruption in a mouse model. In particular, several miRNAs located
in Igf2 and Dlk1-Dio3 imprinted loci were markedly activated following miR-122 loss in liver tissue
from both transient and stable miR-122-KO mice, suggesting initiation of precancerous transcriptional
modifications in mice lacking miR-122 expression [38,39]. These studies emphasize the intriguing
idea of complex regulatory networks and inter-relationships between miRNAs, transcription factors,
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epigenetic modulators and miRNA machinery complexes whose stringent cooperation defines the
precancerous transcriptional phenotype observed in miR-122−/− mice that is, strikingly, shared by
human HCCs.
Notably, in vivo gene targeting of Dlk1-Dio3 locus by AAV vectors causing its overexpression led
to HCC development in 100% of mice and, in line, overexpression of this miRNA cluster associated with
an aggressive stem-cell-like phenotype in HCC [40]. Others and our group reported the upregulation
of miR-494, a member of the Dlk1-Dio3 miRNA cluster, in 25–30% of HCCs with stemness features
and demonstrated its involvement in tumor progression and sorafenib resistance through the direct
targeting of mutated in colorectal cancer (MCC) and the phosphatase and tensin homolog (PTEN)
tumor suppressor gene [15,16]. Regarding IGF2/483 oncogenic locus, an increase of miR-483-3p
was found in 30% of human HCCs and Bcl-2 binding component 3 (BBC3/PUMA), a Bcl-2 family
member with pro-apoptotic functions, was identified among its target genes, suggesting miR-122 KO
models as representative of a subgroup of HCCs with stem-cell-like characteristics and epigenetic
deregulation [41].
4.3. miR-148a KO Mouse Model and Epigenetic Changes
Knockout mice for miR-148a, a liver abundant miRNA, were established to assess its intrinsic role
in liver physiology and to characterize its contribution to hepatocarcinogenesis. Indeed, miR-148a-3p/5p
decreased expression was observed in tumor versus nontumor tissue of HCC patients, and it was
associated with poor differentiation and reduced overall survival. miR-148a-KO mice showed an
increase of steatosis and serum total cholesterol levels, as well as an upregulation of genes involved
in lipogenesis and fatty acid uptake, when fed with both a regular-chow diet (RCD) and high-fat
diet (HFD). As expected, several genes involved in lipid and cholesterol biosynthesis were identified
among miR-148a-3p/5p targets displaying increased levels in KO animals, independently of the
diet. Moreover, tumor induction by a single diethylnitrosamine (DEN) injection led to an increased
number and size of tumor nodules in KO mice, whereas restoring pri-miR-148a levels reduced tumor
count and volume [17]. Interestingly, miR-148a progressive upregulation was detected in a mouse
fetal hepatoblast model when subjected to liver differentiation, which corresponded to an opposite
decrease of its target gene DNA methyltransferase 1 (DNMT1). Functional analysis demonstrated the
involvement of miR-148a/DNMT1 axis in triggering expression of adult hepatic markers, albumin
(Alb), glucose-6-phosphatase catalytic subunit (G6PC), and tyrosine aminotransferase (Tat), and
proved a negative feedback loop between miR-148a and DNMT1 itself. Notably, miR-148a decreased
expression was detected in liver biopsies from HCC patients with respect to normal livers, but not
surrounding tissues, suggesting its involvement in the progression of the underlying liver disease.
Finally, gain-and-loss of function studies demonstrated its role in preventing invasive capabilities of
HCC cells through mesenchymal epithelial transition factor (c-Met) indirect targeting and reported the
oncogene c-Myc among miR-148a transcriptional inhibitors contributing to its downregulation during
hepatocarcinogenesis [42].
4.4. miR-223 KO Mouse and NAFLD
A recent study described the protective activity of the neutrophil-associated miRNA, miR-223, in
nonalcoholic steatohepatitis (NASH) and HCC, by the direct targeting of inflammatory and oncogenic
genes upregulated in these pathologic conditions. HFD-fed C57BL/6J mice developed steatosis but were
resistant toward NASH progression; strikingly, higher tissue levels of the anti-inflammatory miR-223
were found in hepatocytes from HFD-fed mice, as well as in liver specimens from NASH patients, with
respect to control-diet-fed animals and healthy liver samples, respectively. miR-223KO mice developed
a full spectrum of nonalcoholic fatty liver disease (NAFLD) and more severe NASH phenotypes, as
corroborated by higher levels of serum alanine aminotransferase (ALT), greater liver infiltration and
fibrosis, and increased mRNA levels of pro-inflammatory cytokines. In addition, IPA of microarray
data revealed the dysregulation of genes contributing to carcinogenesis and inflammatory response
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in KO with respect to wild type (WT) mice after three months of HFD. In line, half of miR-223KO
animals developed HCC after long-term HFD feeding, showing an increased susceptibility to disease
progression. Since miR-223 positively correlated with several chemokines (C-X-C motif chemokine 10,
CXCL10) and cytokines (interleukin-6, IL-6) and with cancer-related genes (glypican 3, GPC3) in NASH
patients, the authors hypothesized a protective role for miR-223 against malignant transformation and
disease progression, contributing to the explanation as to why HFD feeding alone is not sufficient for
NAFLD progression in mouse models [43]. These interesting findings depicting the anti-inflammatory
role of miR-223 in NASH patients agree with data from other groups, as wee as our own, showing a
downregulation of miR-223 in HCC with respect to surrounding nontumor tissues from surgically
resected HCCs, corroborating the idea that high miR-223 levels restrain tumor development [3,44].
5. Transgenic Mouse Models
5.1. miR-221 TG Mouse
miR-221 is upregulated in 70–80% of HCCs and in a wide range of different malignancies.
The recognition of miR-221 related targets, such as the cyclin-dependent kinase inhibitors CDKN1B/p27
and CDKN1C/p57, PTEN, or the pro-apoptotic protein Bcl2 modifying factor (BMF), explains several
mechanisms through which its upregulation contributes to carcinogenesis [9,10,14]. We developed
a liver-specific miR-221 transgenic mouse model (TG221) which spontaneously develops HCC in
50% of male mice aged 9–12 months. DEN administration accelerates the appearance of liver cancer
that becomes visible at 3–4 months of age in all male mice. Interestingly, in this TG model, the
degree of miR-221 upregulation quantitatively matches the extent of miR-221 deregulation in human
HCC, with a two-to three-fold change when comparing HCC with surrounding tissue. Specifically,
following intraperitoneal DEN injection TG221 animals displayed a higher liver weight associated
with increased number and volume of tumor nodules [18]. Lower expression of miR-221 validated
targets, p27, p57, and Bmf in TG tumors and liver samples with respect to WT animals confirmed this
model as representative of molecular mechanisms previously identified in HCC cell lines and human
tumors [10]. This model was employed to test in vivo the antitumor activity of chemically modified
anti-miR oligonucleotides (AMOs). Briefly, the experimental protocol consisted in one intraperitoneal
(IP) injection of DEN in 10-day newborn TG mice and, two months later, three intravenous (IV)
injections of anti-miR-221 every 15 days. A reduction of size and number of tumors was detected in
the group receiving miR-221 AMOs with respect to control-treated mice, showing a persistent decrease
of miR-221 levels and demonstrating the specificity and efficacy of this therapeutic strategy. Therefore,
the TG221 model confirmed miR-221 as a driver gene for HCC development and progression and
resulted as an effective tool to test miRNA-mimic or anti-miRNA-based approaches increasing the
knowledge regarding their safety, specificity, and efficacy for the treatment of HCC. In this regard,
the expression of several HCC-specific miRNAs, miR-199a-3p, miR-122, and miR-21 in TG221 mice
reflected those observed in primary human HCCs; therefore, this model was employed to assay the
anticancer activity of miRNA mimic oligonucleotides too [18]. Besides anti-miR-221, miR-199a/b-3p
mimics were tested to treat HCCs developed in miR-221 TG mouse. miR-199a-3p represents the
third most abundantly expressed miRNA in the liver, and it is downregulated in virtually all HCCs
with a fold change greater than 10-fold in many cases, representing an ideal candidate for in vivo
replacement therapy [3,45–47]. It controls several cancer-associated genes, such as mammalian target
of rapamycin (mTOR), hepatocyte growth factor receptor c-Met, the kinase p21-activated kinase 4
(PAK4), and the Notch regulator Yes-associated protein 1 (YAP1). Since an miR-221 TG mouse also
displays miR-199a-3p constitutive downregulation, miR-199a-3p mimics were adopted by using two
experimental protocols: DEN priming in 10-day newborn mice followed by three IP injections per
week for three weeks at three or five months of age. Both protocols showed a decreased number and
size of nodules in miR-199a-3p mimics treated group with an anticancer effect similar to that observed
in sorafenib-treated mice [19]. A decrease of mTOR and PAK4 protein expression was observed in HCC
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specimens from miRNA mimics treated animals, confirming similar mechanisms of action observed in
other preclinical models, as well as in human HCCs [3,46]. An interesting finding is that the livers of
miR-221 TG mice are characterized by a relevant steatohepatitis, which resembles the human NASH
that is becoming a more and more prevalent risk factor for HCC [48].
5.2. miR-221 TG Mouse Developing HCC on Liver Cirrhosis
One limitation of most HCC murine models is the absence of cirrhosis, which, instead, accompanies
the multistep natural history of human HCC in about 90% of cases, with the well-known role of
associated microenvironmental changes. Genetic manipulations may modify the expression of key
molecules driving liver carcinogenesis allowing studying specific mechanisms, which, however, take
place on a healthy liver. The preneoplastic stage of cirrhosis represents a background to be kept in
mind when trying to match animal models with human disease. Indeed, cirrhosis is a distinct disease
to face with and its own contribution through microenvironmental changes should be considered
when assaying novel biomarkers or dissecting molecular mechanisms. This is true not only for
molecular purposes, but also for functional reasons when testing the therapeutic/toxic effect of drugs.
Notwithstanding this, the animal models of HCC arisen on a background of overt cirrhosis are very
few. Among these, the HCC mouse model developed by Domenicali and co-authors provides the
background for repeated cycles of liver damage/regeneration to reflect faithfully the events leading
to the development of cirrhosis [49] This model recapitulates the progression from hepatocyte cell
death, proliferation, fibrosis, towards cirrhosis with portal hypertension syndrome. Notably, only
a very restricted fraction of these animals develops HCC. Briefly, a well-tolerated protocol able to
induce cirrhosis in C57BL/6N mice consisted of administration of the carbon tetrachloride (CCl4)
by short inhalation cycles, twice or three times weekly, administered through increasing exposure
times, resulting in a safe and effective method to induce decompensated cirrhosis with ascites.
Conversely, subcutaneous or intraperitoneal CCl4 administration displayed adverse events, preventing
the development of an overt cirrhosis with portal hypertension syndrome. Thus, Callegari et al. applied
this model in mice bearing a genetic factor that predisposed them to HCC, such as the miR-221 TG
mouse [18]. Taking advantage of the protocol developed by Domenicali et al. [49], multiple short-term
inhalation cycles of CCl4 were used to induce decompensated cirrhosis in TG221 transgenic mice, to
test the possibility of inducing liver tumors in the context of cirrhosis. Unlike the very low incidence of
HCC in control mice developing cirrhosis, when applied to TG221 mice at four weeks from the end
of CCl4 treatment, ultrasound analysis revealed large liver nodules which were histopathologically
confirmed as dysplastic nodules or HCC, whereas, in WT mice, most were macro-regenerative or
hyperplastic nodules, without dysplastic features. All animals displayed overt cirrhosis, demonstrated
by histopathological examination, by the presence of ascites, and by activation of fibrotic markers
such α-smooth muscle actin (α-SMA), connective tissue growth factor (CTGF), and transforming
growth factor beta 1 (TGF-1). Notably, in TG221 mice, necro-inflammatory changes were more intense
and extended, and progression to dysplastic nodules or HCCs was confirmed based on morphology,
immunohistochemistry (increased expression of tumor-associated genes such as alpha-fetoprotein ‘AFP’
and ‘GPC3’) and gene expression patterns. This model appears to recreate faithfully the natural history
of HCC on a background of cirrhosis. It could also be considered to investigate microenvironmental
changes associated with disease progression and to achieve functional implications relevant for drug
metabolism and toxicity. In conclusion, the cirrhosis-associated TG221 model represents a robust
preclinical tool for testing therapeutic or prophylactic strategies in a preclinical setting recapitulating
the pathophysiology of human HCC [20].
5.3. miR-17-92 TG Mouse
miR-17-92, together with its paralogous miR-25-106b cluster, is one of the first polycistronic
miRNA clusters whose overexpression was recognized in hematologic and solid tumors [50,51].
miR-17-92 is transcriptionally regulated by c-Myc proto-oncogene, and it is required to maintain a
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neoplastic state through the regulation of genes involved in chromatin remodeling and apoptosis [52,53].
In order to dissect the contribution of miR-17-92 cluster to hepatocarcinogenesis, Zhu and coworkers
investigated its expression in HCC patients and established a transgenic mouse model overexpressing
the six-miRNA family members in the liver. Quantitative polymerase chain reaction (QPCR) analysis
and in situ hybridization (ISH) were performed in two HCC patient cohorts reporting miRNA (miR-17,
miR-18, miR-19a, miR-19b, miR-20, and miR-92) overexpression in tumor tissues with respect to
nontumor specimens; miRNA sequencing data from the Cancer Genome Atlas (TCGA) database
further confirmed their overexpression in a larger cohort of patients. The miR-17-92 TG mouse model
showed augmented propensity to liver cancer induction following DEN administration in comparison
to WT mice, as evidenced by an increase of tumor nodule number and volume at 10-month. In addition,
TG mice displayed a faster tumor progression, showing a higher percentage of HCC nodules [54].
5.4. HBx Transgenic Mouse and miR-224
An intriguing mechanism of miRNA degradation was proposed for miR-224 whose expression
negatively correlated with autophagy in HBV-related HCCs, as demonstrated by the tissue array of
autophagy-associated markers (autophagy related 5 ‘Atg5’, Beclin1, and p62) and ISH for miRNA
detection in a cohort of 93 HCC patients. In particular, a negative correlation between miR-224 and
autophagy-promoter gene Atg5, and a positive correlation between miRNA levels and p62 gene,
whose accumulation typically characterizes autophagy impairment, were displayed in hepatitis B virus
(HBV)-infected patients, but not in hepatitis C virus (HCV)-positive ones. To confirm this peculiar
miR-224/autophagy relationship occurring in HBV-related HCCs and to clarify autophagy-mediated
mechanisms of miRNA regulation, an Hepatitis B Virus protein X (HBx) transgenic mouse model
was used [55]. The oncogenic properties of the HBx gene are indeed well-known and these TG
animals, established in 1991, showed progressive histopathological liver changes progressing to
carcinomas that were fatal to all the animals [56]; thus, they represent ideal models for defining
molecular events involved in HBV-associated liver tumorigenesis. Low Atg5 expression accompanied
by p62 accumulation and high miR-224 levels were detected in tumor specimens with respect to
nontumor tissues of 17.5 months old mice. Notably, only mature miR-224 isoform but not precursor
transcript was upregulated in HCC patients and HBx TG mice, suggesting post-transcriptional events
participating to its regulation. Elegant in vitro experiments with autophagy inducers and inhibitors
demonstrated miR-224 recruitment to the autophagosome and its degradation following fusion with
lysosomes, independently from viral status of hepatoma cells, postulating that induction of autophagy
or miR-224 antagonism are effective antitumor strategies in HCC. In addition, SMAD family member
4 (Smad4) and glycine-N-methyltransferase (GNMT) were described among miR-224 target genes,
and their involvement in liver injury and tumor progression was proved by in vitro and in vivo
models [55,57]. Again, miR-224 upregulation and inverse correlation with its target GNMT were
described in HBV-related HCC patients only, confirming the virus-specificity for miR-224 aberrant
expression [55,57]. Consistently, miR-224 upregulation characterized early stages of HBV-related
hepatocarcinogenesis in different animal models, highlighting the necessity of proper animal models
when virus-related miRNA-based therapeutic options are concerned [58].
Interestingly, Tang and coworkers compared gene-expression profiling between HBX-TG mice
and chemically induced DEN-HCC mice. They showed that upregulated genes in tumor versus normal
tissue were mainly involved in immune and acute-phase response and cholesterol and lipid biosynthesis
in the DEN model, whereas upregulated genes belonged to positive regulation of gene expression,
cell proliferation, migration and invasion, and immune response in the HBX model. On the contrary,
both models shared common deregulated genes involved in metabolic pathways and redox processes.
Moreover, early growth response 1 ‘Egr1’, activating transcription factor 3 ‘Atf3’ and Kruppel-like
factor 4 ‘Klf4’ resulted as the main regulatory factors in HBX mice controlling cancer-associated
signaling pathways, such as PI3K/AKT, MAPK, Ras, and p53, which role in hepatocarcinogenesis is
well established [59]. Notably, several oncogenes and tumor-suppressor (TS) genes deregulated in
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human HCC were controlled by these transcription factors, highlighting the reliability of the HBX
mouse model with respect to the human pathology.
6. Oncogene-Related TG Mice
Myc and Ras are canonical oncogenes whose increased expression, amplification, or pathway
activation has been identified in most of human cancers. Regarding HCC, Ras pathway is often
activated due to promoter hypermethylation of Ras association domain family member 1 (RASSF1) and
novel Ras effector 1A (NORE1A) inhibitors [60]. Interestingly, MYC oncogene was recently associated
with a gene regulatory network formed by lin-28 homolog B (LIN28B), CTNNB1, SWI/SNF Related,
Matrix Associated, Actin Dependent Regulator of Chromatin, Subfamily A, Member 4 (SMARCA4),
Let-7b, SRY-Box Transcription Factor 9 (SOX9), and TP53 that correlated with increased proliferation,
dedifferentiation and c-Met pathway activation more likely contributing to the transcriptional signature
typical of the HCC “proliferation” subclass [61].
Oncogene-inducible liver-specific transgenic mouse model gave rise to liver tumors with a 100%
penetrance within 12 weeks. Histological characterization revealed that Myc-driven tumors resemble
poorly differentiated HCCs or human hepatoblastomas, Ras-driven tumors resemble human HCCs,
and Myc + Ras-driven tumors mirrored an aggressive variant of HCC or fetal variant of hepatoblastoma.
Molecular characterization showed the overexpression of chromosome 12qF1 miRNA megacluster,
comprising 53 miRNAs, in Myc, Ras, and Myc + Ras TG mice and in a subgroup of human HCCs
(human homolog located at chromosome locus 14q32). In particular, a 60-miRNA signature was shared
by these three oncogene-dependent models and was representative of an HCC patients’ subgroup
with high AFP expression, displaying 29 out of 60 members belonging to the Dlk1-Dio3 miRNA cluster.
Since miR-494 showed the highest activity in a colony forming unit assay and increased cell cycle
progression through MCC targeting, the antitumor potential of miR-494 antagonist molecules was
tested in Myc-driven HCC bearing mice showing decreased tumor burden associated with increased
p27 and MCC protein levels [16]. In line, we demonstrated p27 as a miR-494 direct target gene
in HCC cell lines and xenograft mice playing a role in cell cycle fastening and cell proliferation
in miR-494 overexpressing Huh-7 cells, suggesting that both animal models might be suitable for
identification of miR-494 downstream molecular mechanisms [15]. Similarly, miR-206 was commonly
downregulated among c-Myc and AKT/Ras-oncogene induced HCC mouse models, HCC cell lines,
and human HCCs contributing to tumor development and progression through cell cycle regulator
cyclin D1 (CCND1), c-MET, and cyclin-dependent kinase 6 (CDK6) direct targeting, as demonstrated
by in vitro and in vivo experiments [21]. Notably, oncogene overexpression might be obtained not
only through the establishment of TG mice but, more easily, through hydrodynamic tail-vein injection,
which is an efficient procedure to deliver nucleic acids, primarily to the liver, taking advantage of its
peculiar fenestrated sinusoids. By means of a rapid injection of a large liquid volume containing the
specific sequences of interest, mouse models with stable gene expression can be generated. Strikingly,
miR-206 hydrodynamic delivery in concomitance with c-Myc and AKT/Ras oncogenes prevented tumor
formation and cancer-associated death of all animals, emphasizing the suppressor role for miR-206 in
HCC initiation in both oncogene-derived mouse models.
In conclusion, genetically engineered models represent optimal tools for investigating miRNA
involvement in hepatocarcinogenesis (Dicer1KO, miR-122KO), for testing anticancer activity of
miRNA-based therapeutic option (TG221 + DEN; HBx TG; oncogene-related TG mice) and for
recreating the multi-step pathogenic history of HCC development in a cirrhotic (TG221 + CCl4) or
metabolic (miR-223KO) background.
7. HCC Mouse Models and miRNA-Based Therapeutic Approaches
A growing body of evidence support the involvement of miRNAs in the coordination of complex
cellular programs, due to their ability to regulate hundreds or thousands of targets. Since the liver
represents an ideal organ for gene therapy, first in vivo studies demonstrated the nontoxicity and
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efficacy of chemically modified oligonucleotides targeting the liver-specific miR-122 in both rodent and
nonhuman primate species [32,62]. Regarding miRNA-based therapeutic strategies, several pros and
cons have to be considered when clinical trials are concerned. Indeed, on the one hand, the intrinsic
nature of miRNAs as multi-regulators of gene expression represents an advantage for cancer treatment
favoring the targeting of multiple steps of a single pathway, as well as contemporaneous inhibition of
redundant pathways that could represent tumor escape mechanisms associated with drug-resistant
phenotypes. On the other hand, this multitargeting ability might trigger opposite effects, depending on
tissue of origin, but also on cellular context within a single tumor, where the same miRNA might behave
as a tumor-suppressor gene or as an oncogene, depending on constitutive expression of targets [63].
As an example, we reported the dual role for oncomiR-221 in cell proliferation and drug sensitization
based on p53 status, as well as the simultaneous targeting of PTEN tumor-suppressor gene and AKT3
oncogene, both belonging to the AKT/mTOR pathway, by miR-519d, which is strongly upregulated in
50% of HCCs [64,65]. These apparent contradictory functions of miRNAs can be understood when we
consider their physiologic activities and their prominent role that is the fine-tuning of cellular processes,
balancing complex molecular networks at multiple levels. Of note, this equilibrium might be no more
applicable to diseased states such as cancer. Even more importantly, this concept should be considered
when we hypothesize to use miRNAs as therapeutic molecules. In this regard, it is mandatory to
identify those molecular settings in which miRNA manipulation targets specific driver mechanisms.
In the abovementioned case of miR-519d, which targets both PTEN and AKT3, its inhibition in HCCs
with high PTEN expression is able to counteract AKT/mTOR pathway. Conversely, in HCC with PTEN
null expression, it would determine an even stronger AKT/mTOR pathway activation through AKT3
upregulation, contributing to tumor cell proliferation and invasion.
Due to the frequent downregulation of miR-34a in most of human tumors, including HCC, the
first clinical trial testing of a liposomal miR-34a mimics-based formulation is now ongoing in oncologic
patients at advanced stages [66]. Notably, Gougelet and colleagues described the overexpression of
miR-34a in HBV-related HCCs and APC−/− transgenic mice where its silencing by means of locked
nucleic acid (LNA) probes slowed down tumor progression, emphasizing the need for delineation of
accurate patients’ subclasses based on their molecular patterns when miRNA-mediate approaches are
concerned [22]. In this scenario, miRNAs represent optimal target genes and attractive candidates
for single or combined therapeutic strategies. In the abovementioned oncogene-related mouse model
injected with AKT/Ras or c-Myc to induce HCC, the therapeutic potential of two different miR-206-based
molecules was assayed. The first strategy was based on minicircle episomal DNA vectors, which have
a smaller size that enables more efficient delivery and sustained expression in a period of weeks with
respect to greater DNA plasmid vectors. The second strategy considered miRNA mimics modified
at 2’O-methyl and labeled with four cholesterol groups, to increase the stability and transfection
efficiency. Both strategies showed a marked anticancer effect in c-Myc mice, decreasing tumor growth
and target genes expression, but failed to repress tumor growth of AKT/Ras mice, perhaps due to their
more rapid growth, underlining the importance to test miRNA-based therapeutics in different animal
models and suggesting again the need for patient stratification based on genomic and transcriptomic
backgrounds [21]. In the following paragraphs, we describe miRNA-based antitumor approaches in
xenograft and orthotopic HCC mouse models, focusing on their representativeness of human pathology
and translation into the clinics (Figure 1).
8. Xenograft Mice
Xenograft models are obtained by subcutaneous injection of tumor cells into immunocompromised
mice and have been largely used in preclinical studies due to their easy manipulation. They represent
a good tool for a rapid in vivo screening of tumor growth and drug response, even though caution
has to be used when translating results into the clinical practice. Indeed, major disadvantages with
respect to GEM are (1) the absence of a proper immune response by the host and (2) the lack of an
appropriate tumor microenvironment. On the other hand, the advantage of xenograft with respect
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to GEM models is represented by their easy and rapid establishment, as well as by the employment
of human cells that might better reflect human tumor phenotypes and drug response with respect to
mouse tumors. The ability of cancer cells to develop a multidrug resistant phenotype represents a
major obstacle for both standard chemotherapy and molecular targeted therapy leading to treatment
failure and tumor progression and limiting effective chances to cure oncologic patients. The presence of
redundant molecular mechanisms favors tumor escape, and targeting single molecules often activates
compensatory pathways allowing survival of neoplastic/progenitor cells. Since pharmacologic
treatments modify a conspicuous number of signaling cascades, the miRNA-based multiple inhibition
of regulatory elements combined with clinically available drugs might be a successful strategy in the
field of molecular oncology. Regarding HCC, an interesting study by Tang and coworkers described
the antiproliferative effect of an artificial long noncoding RNA (AlncRNA) simultaneously targeting
six miRNAs whose expression is upregulated during sorafenib treatment, namely miR-21, miR-153,
miR-216a, miR-217, miR-494, and miR-10a-5p. Interestingly, PTEN is a common and validated target of
all these miRNAs, as well as the principal negative regulator of the pro-survival AKT/mTOR pathway,
whose activation represents an unfavorable event often occurring in sorafenib-acquired resistance
and promoting cell proliferation and autophagy blockage [67]. Intratumoral injection of adenoviral
particles Ad5-AlncRNA in a sorafenib-resistant xenograft mouse model induced only a slight decrease
of tumor growth but strongly synergized sorafenib antitumor activity, half-reducing tumor weight,
decreasing Ki-67 staining, and increasing terminal deoxynucleotidyl transferase dUTP nick end labeling
(TUNEL)-positive cells with respect to control animals [68]. In agreement, in our experience, the only
overexpression of miR-494 in HCC xenografts does not impact on tumor growth, whereas in the setting
of sorafenib treatment, overexpression of miR-494 determines resistance, suggesting the central role
for miR-494/PTEN/AKT/mTOR/p27 axis in sorafenib sensitization in HCC [15]. He and coworkers
described similar findings reporting the synergistic effect of anti-miR-21 oligonucleotides coupled with
sorafenib in a xenograft model obtained by subcutaneous inoculation of sorafenib resistant Huh-7 cells.
In particular, miR-21 silencing in vivo restored sorafenib sensitization through PTEN targeting and
autophagy activation as assessed by Ki-67 and TUNEL staining as well as by transmission electron
microscopy showing a consistent increase of apoptotic cell death and autophagosome vesicles [23].
In the last years, several efforts were made toward the development of efficient nanotherapeutics for
the delivery of miRNA-based oligonucleotides, increasing organ-specific targeting and reducing miRNA
degradation by systemic endonucleases. Interestingly, a recent study developed a straightforward
strategy to deliver miR-375 in HCC cells in both in vitro and in vivo studies assembling miRNA
mimics molecules on the surface of gold nanoparticles (AuNP). Several properties make these
oligonucleotide-functionalized nanoparticles ideal for biomedical applications, such as their ability
to be captured and internalized by cultured cells or animal tissue without the aid of other carriers,
the increased nuclease resistance of coated miRNAs and a lower activation of host immune response.
Intratumoral injection of miR-375 nanoparticle formulation markedly reduced tumor growth of
HepG2 xenograft masses. These findings were confirmed in a second HCC mouse model obtained
by hydrodynamic injection of AKT/Ras oncogenes and tail-vein administration of AuNP-miR-375
showing a consistent increase of apoptotic markers and a reduction of tumor nodules and hepatocyte
proliferation [24].
Several considerations arise from studies on xenograft models: (i) the contemporaneous
modulation of different miRNAs targeting common pathways might help control tumor recurrence
and drug-resistant phenotypes (lnRNA-mediated approaches); (ii) the combination of miRNAs and
chemotherapeutics or targeted molecules might potentiate drug efficacy (miR-494 and miR-21 combined
with sorafenib); (iii) the development of delivery systems favors optimal miRNA uptake by cancer cells.
9. Patient-Derived Xenograft Mice
The employment of patient-derived xenograft (PDX) mice shows several advantages over
cell-line-derived xenografts: (1) maintenance of genetic and epigenetic abnormalities and clonal
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heterogeneity existing in the primary tumors; (2) stroma cells from the tumor can be implanted,
mimicking the tumor microenvironment; and (3) stronger predictive results that might aid in choosing
the best therapeutic strategy for the patient.
An interesting study by Hou and collaborators described the results from a quantitative
analysis of miRNA abundance in the liver and identified miR-199a/b-3p as the third most highly
expressed miRNA resulting in deregulated in almost all HCC cases, independently from etiologic
factors. Interestingly, nine miRNAs accounted for 88.2% of the liver miRNAome and specifically
miR-122, miR-192, and miR-199a/b-3p represented 52%, 16.9%, and 4.9%, respectively. In addition,
epigenetic modifications of histones mediated miR-199a/b-3p downregulation in HCC, which was
associated with decreased tumor-free results and overall survival in two patient cohorts, activating
the oncogenic Raf/MEK/ERK signaling cascade. Regarding in vivo models, a patient-derived mouse
model was established by subcutaneous transplantation of fresh tumor tissue in nude mice and masses
propagated by sequential subcutaneous passages. Different miRNA delivery strategies were assayed,
consisting of intratumoral injection of cholesterol-conjugated miR-199a/b-3p mimics or AAV vector
particles inhibiting tumor growth, decreasing AFP levels, and causing tumor necrosis. In addition,
AAV-mediated miR-199a/b-3p delivery by a single tail-vein injection in patient-derived orthotopic mice
showed increased miRNA levels in tumor tissue, together with reduced tumor size, demonstrating
the efficacy and nontoxicity of AAV8 vector system for potential HCC gene therapy [46]. Findings
here obtained with miR-199a-3p-based therapeutics agree with those reported in the TG221 mice,
proving the reliability of these animal models and suggesting miR-199a-3p replacement as a promising
therapeutic option for human HCC [19].
In this scenario, the targeting of multiple oncogenic miRNAs by lncRNA-based vector engineering
is emerging as a winning and innovative therapeutic strategy avoiding cancer cells to bypass the
inhibition of a single miRNA and regain their proliferation capabilities. Li and coworkers generated an
artificially designed interfering long noncoding RNA (lncRNAi), which contains the complementary
sequences to multiple oncomiRs, competing with their target genes to bind to and consume oncomiRs
inside HCC cells. Among oncomiRs overexpressed in HCC, this lncRNAi oncolytic vector was designed
to selectively target miR-21, miR-221/222, miR-224, miR17-5p/20a, miR-10b, miR-106b, miR-151-5p,
miR-155, miR-181a/181b, miR-184, miR-1, and miR-501-5p and showed multiple effects on transduction
pathways, playing a key role in proliferation, invasion, and apoptosis of HCC cells. Two animal
models were employed in this study (xenograft and PDX mice), one receiving intratumoral injection of
lncRNAi oncolytic vectors and the other control vectors. A significant decrease of tumor growth was
observed in both models, showing a decrease of target miRNAs and a correspondent increase of the
most representative target genes, p27 and PTEN, highlighting this multi-miRNAs-based approach as a
promising strategy with a greater anticancer efficacy in HCC [69].
10. Orthotopic Mice
Considering the importance of tumor microenvironment or tumor ‘niche’ for malignant
transformation of normal hepatocytes and for development and progression of tumor nodules,
the employment of orthotopic xenografts should be favored when testing drugs acting on tumor
microenvironment. An innovative in vivo bioengineering approach has been established for the
development of miRNA-based cancer therapies, producing a panel of biologic miRNA/siRNA
molecules containing a common tRNA/pre-miR-34a molecular scaffold expressed at high levels
by Escherichia coli fermentation. The production of these oligonucleotides in living cells guarantees
minimal post-transcriptional modifications with respect to heavy chemical modifications applied to
oligonucleotides produced by chemical synthesis; moreover, their correct processing and specific
activity have been reported in human cells [70]. Interestingly, bioengineered let-7c displayed the
highest antiproliferative activity against Huh-7 cells and reduced protein levels of validated targets,
such as LIN28B, c-Myc, AT-rich interactive domain-containing protein 3B (ARID3B), and Bcl-xl, in both
Hep3B and Huh-7 cells, as well as stem-cell properties of Huh-7 cells. An orthotopic HCC xenograft
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model was employed to test in vivo the efficacy of a lypopoliplex (LPP)-let-7c formulation, displaying
a significant reduction of tumor burden associated with decreased AFP serum levels and increased
apoptotic markers. LPP-formulated let-7c nanotherapeutics were well tolerated in vivo, showing
minimal immunogenicity in human peripheral blood mononuclear cells and immunocompetent mice
and holding great promise for the development of miRNA-based therapeutic options entering clinical
experimentation [25].
A crucial aspect regarding gene replacement therapy is represented by the abundance of gene
expression in normal tissue, reducing the risk of side effects, favoring treatment tolerance, and
restricting antiproliferative and proapoptotic effects to cancer cells. miR-26 is expressed at high
levels in several tissues but is downregulated in liver tumors, altering cell proliferation of HCC
cells through direct targeting of cyclins D2 (CCND2) and E2 (CCNE2). The antitumorigenic effect of
AAV-mediated miR-26 replacement strategy was previously reported in a c-MYC transgenic model of
liver cancer, resulting in inhibition of cancer cell proliferation and tumor progression [26]. In addition,
Jin et al. reported that miR-26 restoration is able to promote doxorubicin sensitization through
autophagy inhibition by direct targeting of Unc-51 like autophagy activating kinase 1 (ULK1) gene
that is responsible for autophagosome enucleation regulating initial steps of autophagic program.
In particular, an orthotopic mouse model was established by implanting HepG2 cells in livers of nude
mice, showing that miR-26 was able to increase drug sensitivity by blocking autophagy and therefore
reducing tumor cell proliferation and triggering apoptotic cell death [27]. Notably, miR-26 family
members were also downregulated in our DEN-HCC rat model (miR-26a-5p and miR-26b-5p; raw
data are available in ArrayExpress repository, accession number E-MTAB-7624), again highlighting the
similarities between rodent and human HCC biology and emphasizing the importance of a thoughtful
animal model choice when translational studies are concerned, privileging studies with at least two
different preclinical models.
11. Rat Models
HCC rat models do not allow genetic manipulation as mouse models do. However, execution of
specific treatments such as transcatheter arterial chemoembolization (TACE), bile duct ligation, and
surgical procedures are easier in rats than in mice [71]. Same applies to noninvasive monitoring of
HCC development by ultrasound (US). HCC rat models display a high analogy to histopathological
progression of human HCC and are of great value to identify effective anticancer treatments. Here, we
describe the most characterized rat models in terms of molecular match with human HCC and miRNA
deregulation: the DEN-HCC and the resistant-hepatocyte (R-H) rat models. We also report data about
cirrhotic rats developing HCC, which were investigated to test miRNA-based therapeutic approaches.
12. Chemically Induced Rat Model
Due to the essential role of the liver in metabolism and detoxification, several chemical agents
inducing liver injury are used as HCC promoters. DEN is a chemical carcinogen with the potential to
cause tumors in various organs, including the liver, gastrointestinal tract, and respiratory tract [72].
DEN causes genomic mutations by inducing ethyl adducts and alkylation at many DNA positions [73].
Initiation of carcinogenesis, promotion, and progression can be produced by modulating DEN
dosage [72]; in fact, it can induce benign and malignant liver lesions in rats with a high success and a
low mortality rate, providing a model that simulates the lesions occurring in human liver. Induction of
HCCs is usually obtained by administering DEN in the drinking water (100 mg/L) for eight weeks
and one month after the last day of DEN administration multiple nodules can be observed with a size
ranging from 2 to 10 mm in diameter [74,75]. By using this approach, we obtained rat HCCs sharing
histopathological features of human HCC (Figure 2). Other protocols of DEN administration, such
as injection (30 mg/kg body weight twice a week for 11 weeks), followed by a further nine weeks of
observation, were also used, and they were reported to reproduce the inflammation-fibrosis-cancer
stepwise histopathological progression similar to human HCC [76].
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Figure 2. Features of human and rat hepatocellular carcinoma. Hematoxylin-eosin staining of human 
(H1–H3) and rat (R1–R3) HCC showing common histopathological features. (H1–R1) Clear cell 
variant caused by glycogen or lipid accumulation. (H2–R2) Trabecular growth pattern. Neoplastic 
hepatocytes, with nuclear irregularity, are arranged in trabeculae larger than three cell plates. (H3–
R3) Progression toward less-differentiated histopathological grades is marked by the appearance of 
irregular nuclei, nuclear, and cellular pleomorphism, frequent mitosis, and loss of trabecular or 
pseudoglandular structures. Original magnification 40×. Scale bars: 100 µm. 
DEN models have been used in many studies aiming at HCC characterization. Next-generation 
sequencing (NGS) technologies provided new opportunities to identify HCC molecular signatures 
contributing to treatment optimization. In this context, we compared transcriptomic data from 
human and DEN-induced rat HCCs. Among common deregulated genes, the activation of Notch 
pathway and the aberrant expression of a panel of HCC-associated miRNAs (e.g., miR-122, miR-221, 
and let-7a) suggested this model to be suitable to explore miRNA contribution to disease progression 
and treatment response [77–79]. Remarkably, most of miRNAs deregulated in the DEN-induced rat 
model are aberrantly expressed in human HCC cohorts from several studies, as summarized in Table 
1 and Table 2. In particular, members of both paralogous clusters, miR-17-92 and miR-25-106b, 
showing oncogenic properties [54], were upregulated in our DEN-HCC rat model (miR-18a-5p and 
miR-106b-5p; raw data are available in ArrayExpress repository, accession number E-MTAB-7624), 
as well as in our HCC patient datasets (miR-18a and miR-25) [3]. Similarly, miR-122 was 
downregulated in 70% of rat DEN-HCCs (unpublished data from our group) and in the same 
percentage of human HCCs [3]. Let-7 miRNA family, miR-26a, and miR-145 were also 
downregulated in the rat model mirroring human HCC (Table 1 and Table 2). 
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rno-miR-378a-5p 18.3 <0.0001 NA NA NA 
rno-miR-22-5p 11.9 0.012 NA NA NA 
rno-miR-338-3p 11.5 0.0017 DOWN; DOWN; NA 
NA; HIF1A;  
PKLR 
[80–82] 
rno-miR-455-3p 10.1 0.0011 DOWN STK17B [83] 
rno-miR-144-3p 8.7 0.0011 DOWN; DOWN SMAD4; CCNB1 [84,85] 
rno-miR-203a-3p 7.7 0.014 DOWN GPC3 [86] 
rno-miR-352 6.3 0.0098 Rodent-specific miRNA 
Figure 2. Features of human and rat hepatocellular carcino a. Hematoxylin-eosin staining of human
(H1–H3) and rat (R1–R3) HCC showing common histopathological features. (H1–R1) Clear cell variant
caused by glycogen or lipid accumulation. (H2–R2) Trabecular growth pattern. Neoplastic hepatocytes,
with nuclear irregularity, are arranged in trabeculae larger than three cell plates. (H3–R3) Progression
toward less-differentiated histopathological grades is marked by the appearance of irregular nuclei,
nuclear, and cellular pleomorphism, frequent mitosis, and loss of trabecular or pseudoglandular
structures. Original magnification 40×. Scale bars: 100 µm.
DEN models have been used in many studies aiming at HCC characterization. Next-generation
sequencing (NGS) technologies provided new opportunities to identify HCC molecular signatures
contributing to treatment optimization. In this context, we compared transcriptomic data from human
and DEN-induced rat HCCs. Among common deregulated genes, the activation of Notch pathway
and the aberrant expression of a panel of HCC-associated miRNAs (e.g., miR-122, miR-221, and
let-7a) suggested this model to be suitable to explore miRNA contribution to disease progression and
treatment response [77–79]. Remarkably, most of miRNAs deregulated in the DEN-induced rat model
are aberrantly expressed in human HCC cohorts from several studies, as summarized in Tables 1 and 2.
In particular, members of both paralogous clusters, miR-17-92 and miR-25-106b, showing oncogenic
properties [54], were upregulated in our DEN-HCC rat model (miR-18a-5p and miR-106b-5p; raw
data ar av ilable in ArrayExpr ss repo itory, accession nu ber E-MTAB-7624), as well as in our
HCC patient datasets (miR-18a and miR-25) [3]. Similarly, miR-122 was d wnregulated in 70% of
rat DEN-HCCs (unpublished data from our group) and in the same percentage of human HCCs [3].
Let-7 miRNA family, miR-26a, and miR-145 were also downregulated in the rat model mirroring
human HCC (Tables 1 and 2).
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rno-miR-203a-3p 7.7 0.014 DOWN GPC3 [86]
rno-miR-352 6.3 0.0098 Rodent-specific miRNA
rno-miR-30b-3p 6.2 0.0040 NA NA NA
rno-miR-10b-5p 5.6 0.012 UP; UP HOXD10; CSMD1 [87,88]
rno-miR-99a-3p 5.6 0.0016 NA NA NA
rno-miR-210-3p 5.5 0.0083 UP; UP VMP1; HIF3A [89,90]
rno-miR-362-3p 5.1 0.0083 UP; DOWN TOB2; RAB23 [91,92]
rno-miR-30e-3p 5.0 0.0061 NA NA NA
rno-miR-511-3p 4.7 0.0083 DOWN; DOWN NA; AKT1 [93,94]
rno-miR-193-5p 4.3 <0.0001 DOWN; DOWN NA; SPOCK1 [95,96]
rno-miR-33-5p 4.1 0.0021 NA NA NA
rno-miR-192-3p 4.1 0.0056 NA NA NA
rno-miR-3547 3.7 0.0059 Not annotated human miRNA
rno-miR-145-5p 3.7 0.011 DOWN; DOWN;DOWN; DOWN NA; IRS1; IRS2; NA [3,58,97,98]
rno-miR-378b 3.5 0.0039 NA NA NA
rno-miR-122-3p 3.1 0.0068 DOWN MDM2 [99]
rno-miR-339-3p 3.0 0.016 NA NA NA
rno-miR-30a-3p 3.0 0.012 DOWN NA [100]
rno-miR-101a-3p 2.6 0.0010 DOWN; DOWN;DOWN MCl-1; SOX9; EZH2 [101–103]
rno-miR-193-3p 2.4 0.0011 DOWN;DOWN; NA uPA; NA; CCND1 [95,104,105]
rno-miR-365-3p 2.2 0.013 DOWN; DOWN;DOWN NA; ADAM10; RAC1 [106–108]
rno-miR-347 2.2 0.0047 Not annotated human miRNA









rno-miR-122-5p 2.1 <0.0001 DOWN; DOWN CGN1; ADAM10, SRF,Igf1R [3,114]
rno-miR-140-3p 2.0 0.016 NA GRN [115]
rno-miR-101b-3p 1.9 0.0054 DOWN; DOWN;DOWN
MCl-1; SOX9;
EZH2 [101–103]
rno-miR-10a-5p 1.8 0.015 UP; NA EphA4; NCOR2 [116,117]
rno-miR-22-3p 1.8 0.0041 DOWN; DOWN;DOWN HDAC4; YWHAZ; CD147 [118–120]












rno-miR-99a-5p 1.7 0.0013 DOWN; DOWN;DOWN
MTOR, IGF-1R; PLK1;
AGO2 [127–129]
rno-miR-451-5p 1.6 0.011 DOWN; DOWN;DOWN; DOWN
IKBKB; ATF2; c-Myc;
YWHAZ [130–133]
rno-miR-30e-5p 1.6 0.003 DOWN MTA1 [134]
rno-miR-192-5p 1.6 <0.0001 DOWN; DOWN;DOWN ZEB1; SLC39A6; HOTTIP [135–137]
rno-miR-140-5p 1.6 0.0028 DOWN; DOWN;DOWN
TGFBR1, FGF9; Pin1;
FEN1 [138–140]
rno-miR-345-5p 1.5 0.0046 DOWN; DOWN IRF1; YAP1 [141,142]
rno-miR-30d-5p 1.5 0.0097 UP; UP GNAI2; GLDC [8,143]
NA: data not available; UP: upregulated miRNAs in human cohorts; DOWN: downregulated miRNAs in
human cohorts.
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rno-miR-146b-5p 55.6 <0.0001 DOWN; DOWN TRAF6; NA [3,144]
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rno-miR-182 8.3 <0.0001 UP; UP MTSS1; FOXO1 [146,150]
rno-miR-1249 5.3 0.018 NA HNRNPK [151]
rno-miR-3473 4.1 0.0050 Rodent-specific family
rno-miR-466b-5p 3.2 0.016 Rodent-specific family
rno-miR-466c-3p 3.2 0.043 Rodent-specific family
rno-miR-1949 3.0 <0.0001 Rodent-specific family
rno-miR-96-5p 2.7 <0.0001 UP; UP NA; FOXO1 [12,146]
rno-miR-15b-5p 2.0 <0.0001 UP; UP; UP NA; Rab1A;NA [152–154]
rno-miR-93-5p 1.9 <0.0001 UP; UP; UP NA; PDCD4; NA [12,155,156]
rno-miR-130a-3p 1.8 <0.0001 DOWN; DOWN NA; NA [3,157]
rno-miR-106b-5p 1.8 <0.0001 UP; UP; UP NA; DR4;PTEN [158–160]
rno-miR-25-3p 1.7 <0.0001 UP; UP RhoGDI-1; SOCS5 [149,161]
rno-miR-31a-5p 1.7 0.0076 UP; DOWN NA; HDAC2, CDK2 [162,163]
rno-miR-29b-3p 1.5 0.023 DOWN; DOWN Bcl-2, Mcl-1; LOXL2 [164,165]
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The DEN-induced HCC rat model was also used to examine pathways involved in sorafenib
response, showing the modulation of apoptotic and proliferative pathways, and to test the therapeutic
role of siRNAs/miRNAs. In particular, miRNAs are more attractive than siRNAs due to their
simultaneous effects on different pathways. Interestingly, compound Astragalus and Salvia
miltiorrhiza extract (CASE) containing active principles extracted from Astragalus membranaceus and
Salvia miltiorrhiza provided anticancer therapy more likely through miR-145 and miR-21 upregulation
and downregulation, respectively [166].
miR-494 is overexpressed in the great majority of rat DEN-induced HCCs, and its expression
correlates with stem-cell features, representing an appropriate model for studying molecular alterations
occurring in the stem-cell-like HCC subgroup with miR-494 aberrant expression and poor survival (25%
of human HCCs) [15]. Pollutri et al. also demonstrated an antitumor effect of a sorafenib-combined
anti-miR-494 strategy in DEN HCC rats, showing decreased tumor progression with respect to sorafenib
monotherapy. miR-494-mediated mTOR pathway activation was responsible for decreased sorafenib
sensitization in HCC preclinical models; indeed, rapamycin co-administration triggered apoptotic cell
death in miR-494 overexpressing HCC cells, as evidenced by Poly adenosine diphosphate [ADP-ribose]
polymerase 1 (PARP-1) and caspase-3 specific cleavage. Remarkably, all these findings were replicated
in xenograft mice, emphasizing the usefulness of both models for HCC preclinical studies. In the same
model, miR-221 overexpression associated with sorafenib resistance and caspase-3 was recognized as
its target gene, contributing to miR-221 anti-apoptotic activity and drug-resistant phenotype. Notably,
an association between high miR-221 or low caspase-3 levels and tumor multifocality was assessed
in human HCC specimens, suggesting the robustness and specificity of preclinical data and their
reliability with respect to the human pathology [167].
Chemically induced models are advantageous to study HCCs developed in a natural background
of liver damage. However, age of the animals and hepatotoxins concentration might lead to different
tumor phenotypes, influencing experimental outcomes. Remarkably, DEN-induced liver tumors
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were responsive to sorafenib treatment, whereas orthotopically implanted rat HCCs were not [168].
These findings point out differences in treatment responses between models that might be related to
tumor microenvironment and might have a translational impact. As observed for mouse models, the
relevance of cirrhosis in the natural history of human HCC development has prompted researchers to
recreate this background in laboratory models, too. Experimental approaches used to induce liver
damage progressing to cirrhosis in rats include heterogeneous protocols of exposure to CCl4, DEN,
bile duct ligation, or a combination of these [169]. Some studies performed in HCC rat models arising
on cirrhosis have specifically addressed the role of miRNAs as possible treatments for helping liver
regeneration of non-neoplastic hepatocytes after partial hepatectomy, without triggering proliferation
of residual HCC cells. Indeed, the impaired regenerative ability of cirrhotic liver following liver
resection still represents an important risk factor for post-hepatectomy liver failure. In the study by
Chen and coworkers, liver cirrhosis was induced by intraperitoneal injection of 50% CCl4-olive-oil
solution in adult male Wistar rats [170]. In a first study conducted in cirrhotic rats undergoing partial
hepatectomy, miR-203 mimics enhanced proliferative signals promoting liver regeneration such as
IL6/STAT3, favoring the proliferation of normal hepatocytes. Even more interestingly, the same research
group further demonstrated a dual role of miR-203 by addressing the problem of HCC control after
partial hepatectomy, which may trigger growth and metastasis of residual HCC cells. In particular,
Zheng et al. induced cirrhosis and HCC through a sequential exposure of CCl4 and DEN, reproducing
progression of HCC in human cirrhotic livers [171]. These Authors confirmed miR-203 as an enhancer
of liver regeneration after 70% hepatectomy through targeting of IL-6/SOCS3/STAT3 signaling. At the
same time, they demonstrated a tumor suppressive effect of miR-203 on HCC cells. Indeed, miR-203
mimics inhibited proliferation, invasion, and lung metastasis of residual HCC cells by suppressing
epithelial-to-mesenchymal transition (EMT) through IL-1b, Snail1, and Twist1 targeting. The dual
role of miR-203 is not so unexpected; indeed, the same miRNA may act in opposite ways not only in
different tissues, but also in the same tissue, depending on the constitutive expression of targets.
13. R-H Rat Model
Hepatocarcinogenesis is a multistep process characterized by the progressive accumulation of
genetic mutations, epigenetic changes, and chromosomal rearrangements that, together with chromatin
instability, give rise to hepatocyte transformation and the onset of heterogeneous tumors. Because
of limitations associated with tissue availability at early stages, animal models that fully recapitulate
HCC history represent valuable tools for comprehensive studies on molecular alterations involved in
its early development. The resistant-hepatocyte (R-H) rat model consists of a single carcinogenic dose
of DEN followed by a short-term dietary exposure to 2-acetylaminofluorene (2-AAF) that suppresses
growth of virtually all normal hepatocytes, combined to partial hepatectomy (2/3 of rat liver) to sharpen
the rapid proliferation of DEN-altered hepatocytes. After one week from partial hepatectomy, hepatic
foci will continue to proliferate, becoming the precursor lesions that, only in part, will evolve into HCC
nodules [172]. This rat model represents an ideal preclinical tool for the study of molecular events
occurring at very early stages of hepatocarcinogenesis, allowing the identification of phenotypically
distinct lesions that can be easily isolated by means of laser capture microdissection (LCM). The evolution
of preneoplastic lesions has been characterized as showing a positivity for the hepatocyte progenitor
cell marker, cytokeratin-19 (CK19), in 25% of preneoplastic nodules, in 50% of persistent lesions, and in
all HCCs, demonstrating that CK19-positive preneoplastic lesions are more likely the progenitor of
HCC in this model. Comparative functional genomics showed that CK19-associated gene signature
could predict clinical outcomes of HCC patients, representing an ideal model for the study of the
HPC-derived HCC subclass [173]. miRNA and gene-expression profiling identified the activation of
nuclear factor erythroid related factor 2 (NRF2) pathway and upregulation of miR-200a as the prevalent
molecular alterations occurring at very early stages of tumorigenesis and maintained throughout
the carcinogenic process. NRF2 is an integrated redox signaling system controlled by Kelch-like
ECH-associated protein 1 (KEAP1), which promotes its proteasome-mediated degradation and whose
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regulation is modulated by miR-200a itself. The association between miR-200a/KEAP1/NRF2 axis
and tumorigenic potential was proven by in vivo experiments, showing that NFR2 pathway is turned
off during tumor regression of HCC nodules. Because of the high concordance between altered
genes in rat and human tumors, the R-H model also represents an ideal tool for the detection of
miRNA alterations occurring at very early stages of cancer development and for the identification
of target genes and innovative therapeutic strategies [174]. In addition, the activation of NRF2
pathway is also responsible for the upregulation of glucose-6-phosphate dehydrogenase (G6PD), a key
enzyme implicated in metabolic shift or ‘Warburg effect’, through miR-1 inhibition [175]. High G6PD
expression levels were detected in CK19-positive lesions and early preneoplastic foci, but not in
CK-19-negative lesions, and, in line, increased G6PD mRNA levels were observed in two HCC patient
cohorts where it positively correlated with CK19 expression, higher tumor grade, and increased
metastasis formation. In agreement, a negative correlation between miR-1 and G6PD was identified
in CK19-positive lesions, and lower miR-1 levels were quantified in human HCCs with respect to
surrounding livers, confirming the high concordance in terms of dysregulated pathways between
aggressive preneoplastic rat lesions and human HCCs [176]. Interestingly, a global proteomic analysis
from glutathione S-transferase-P (GST-P) positive laser micro-dissected nodules identified G6PD among
protein markers discriminating R-H model-derived focal lesion from normal liver with or without
progenitor cell activation, demonstrating LCM coupled with mass-spectrometry-based proteomics as
an effective approach to characterize preneoplastic lesions and to identify early diagnostic markers
for effective clinical intervention. In addition, mTOR pathway was found activated at early stages of
carcinogenesis and, consistently, its transient inhibition by rapamycin treatment impaired the growth of
focal lesions and induced a less aggressive phenotype attenuating the loss of differentiating functions,
as detected by both transcriptomic and proteomic genome-wide analyses [177,178]. The AKT/mTOR
pathway is frequently activated in HCC, characterizing a subgroup of patients with a high proliferation
signature and sorafenib resistance [179–181]. Several miRNAs contribute to its post-transcriptional
regulation mediating sorafenib resistance in preclinical models, highlighting its central role in HCC
progression and treatment escape [11,15,68,114,167]. Interestingly, the R-H model is also suitable for
the investigation of oval cell population, due to its rapid expansion following partial hepatectomy.
The Hippo pathway is required for the repression of oval cells that represent the adult liver’s stem-cell
compartment. An accumulation of YAP1, a transcriptional co-activator of the Hippo pathway, was
detected in preneoplastic foci, representing a very early event in hepatocarcinogenesis. On the contrary,
a decrease of miR-375 was found in rat early lesions, suggesting its contribution to YAP1 accumulation
and HCC development and confirming its role as a TS miRNA in HCC [182]. Remarkably, the
downregulation of thyroid hormone receptor beta (THRB) was identified as an early event in the R-H
model, but it was not associated with genetic mutations or DNA methylation of its promoter region.
On the other end, among miRNAs directly targeting THRB mRNA, miR-27a, miR-181a, miR-146a, and
miR-204 were upregulated in rat HCCs, and, in particular, miR-27a showed an inverse correlation
with THRB levels and inhibited its expression in HCC cell lines. Regarding human HCC, reduced
expression of THRB target genes, iodothyronine deiodinase 1 (DIO1) and G6PC, was confirmed in
cirrhotic samples with respect to normal livers, suggesting the alteration of this pathway as an early
event in human HCCs, as well. In agreement, an upregulation of miR-181a, miR-27, and miR-204
was detected in surrounding cirrhotic livers, more likely contributing to THRB modulation in liver
cirrhosis and increasing HCC risk development due to the so-called ‘field effect’, further strengthening
the similarities between the RH-model and the human counterpart [183]. Similarly, Brockhausen and
coworker reported the increased expression of miR-181a in human and rodent cirrhotic livers when
compared to normal livers and demonstrated its involvement in TGF-β-mediated EMT in immortalized
non-neoplastic human hepatocytes [184]. TGF-β is a signaling pathway strongly activated in chronic
liver disease, further supporting the possible role for miR-181a in neoplastic transformation in a milieu
of chronic inflammation [184,185]. In addition, lncRNA CCAT1 was demonstrated among molecular
mechanisms contributing to miR-181a deregulation through a sponging activity leading to increased
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cell proliferation and ATG7-mediated autophagy of HCC cells [186]. Concerning autophagy, the
R-H rat model was employed to investigate whether its dysregulation might occur at early stages
of liver carcinogenesis. Controversial data report the dual role of autophagy in cancer, acting both
as a cell survival process and as a tumor suppressor pathway, likely suppressing tumor growth at
early stages and favoring cell proliferation and energy supply at later stages [187]. The study by
Kowalik and coauthors reported an impairment of autophagy in preneoplastic lesions characterized
by accumulation of abnormal mitochondria and autophagic vacuoles with partially degraded material,
displaying an early deregulation of autophagy during hepatocarcinogenesis. An increase of autophagic
markers, Ambra1, Beclin1, and p62 was detected in CK19-positive nodules only. Strikingly, a 150-fold
upregulation of the oncogenic autophagy-related miRNA, miR-224, was detected in these lesions, and
its accumulation is more likely associated with the deregulation of autophagic machinery. In vivo
experiments with amiodarone, an autophagic inducer, showed augmented tumor progression with
increased size of CK19-positive lesions, and, vice versa, treatment with the autophagy inhibitor
chloroquine reduced size and percentage of CK19-positive nodules [188]. Due to the contradictory
role of autophagy in tumorigenesis, particular attention should be given when a pharmacological
strategy is concerned, considering the employment of different animal models to better guarantee the
translation of preclinical findings into the clinics. Others and our group compared this model with the
rat DEN HCCs and described similar alterations, which were confirmed in patient cohorts, as well,
emphasizing the robustness of these preclinical tools. Specifically, a prominent downregulation of the
2-hydroxy acid oxygenase (HAO2) was observed in the R-H rat model at both early and advanced
stages of carcinogenesis. HAO2 was significantly downregulated in 100% of animals from two other
HCC rat models, as well as in two mouse models of HCC (with and without DEN administration), and
in human HCCs, demonstrating HAO2 repression as a general mechanism contributing to liver cancer
development more likely due to reduced reactive oxygen species levels in transformed cells [189].
A time-course gene-expression profile for Aldo-keto reductase (Akr) family members in preneoplastic
and tumor lesions identified the upregulation of six of its members in the R-H rat model, representing
possible markers of early diagnosis. This enzyme superfamily contributes to the metabolism of steroids,
carbohydrates, prostaglandins, aldehydes, and ketones, and their high representation in HCC has been
previously reported by proteomic investigations [190]. The overexpression of two out of six members
was confirmed in DEN-HCC rats and in human liver biopsies at both mRNA and protein levels,
and, as mentioned above, NRF2 nuclear translocation was detected in tumor samples, confirming
the central role of this transcription factor in promoting liver cancer [191]. In conclusion, the R-H rat
model represents a helpful tool for the discovery of dysregulated events occurring at early stages of
tumorigenesis, showing a high translational potential because of great representativeness of molecular
pathways altered in human HCC.
14. Zebrafish
Although zebrafish are less complex than humans, their liver is similar in structure to a mammalian
liver, with biliary epithelial cells, sinusoidal endothelial cells, and hepatic stellate cells that support
hepatocytes [192]. A zebrafish liver develops HCC similar to human liver, and it can be used to study
putative driver mutations found in HCC. Zebrafish and human HCCs share overlapping expression
profiles of genes involved in apoptosis, DNA replication, cell adhesion, metastasis, cytoskeletal
organization, cell motility, cell cycle/proliferation, RNA processing, and protein synthesis. Thus,
zebrafish liver tumors are highly analogous to human HCC in terms of comparative analyses of
microarray data [193]. Upregulated and downregulated genes in zebrafish liver tumors are also
constantly upregulated and downregulated in human HCCs [194]. MicroRNAs are known to be
evolutionary conserved across species. Among them, miR-122 was found to be conserved in 12 different
species, including humans, frogs, and zebrafish, and it is involved both in human and zebrafish
hepatocytes differentiation [195,196]. Moreover, several putative target genes of the miR-1, miR-146,
and miR-221/miR-222 families are conserved between human and zebrafish. Hepatocyte differentiation
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is directed by a positive-feedback loop that includes the transcription factor (HNF6) and microRNA
(miR-122), both in human and in zebrafish liver [197]. According to its tumor-suppressor function in
human HCC, miR-145 expression regulates zebrafish embryonic liver size by controlling hepatocyte
proliferation [198]. Functional analysis in zebrafish shows that miR-30a is required for normal
hepatobiliary development, suggesting a similar critical role in mammalian hepatogenesis [199].
The conserved expression signatures of these miRNAs and the involvement of their predicted target
genes in cancer support zebrafish as a model of liver cancer representative of the human counterpart.
Following injection of the human HCC cell line JHH6 into the yolk sack of Zebrafish larvae,
Tonon et al. confirmed this model as a useful setting to test therapeutic molecules for HCC [200].
Moreover, injecting human cancer cells into zebrafish embryos when the immune response is not
yet established, prevents their rejection. More recently, small molecules with strong anticancer
therapeutic potential and better therapeutic index than sorafenib were identified by using a zebrafish
drug-screening platform [201]. As reported in others HCC animal models, the role of metformin on
HCC tumor surveillance was also demonstrated [202]. Interestingly, as observed in humans, male
fish developed HCC faster than females due to sex hormone imbalance via noncanonical estrogen
signaling, including G protein–coupled estrogen receptor 1 (GPER) [203]. In line, fish treated with
17 β-estradiol developed more tumors than controls, and this effect was evident in particular in
male cohorts [204]. Together with transgenic technology, several inducible expression systems are
available for zebrafish. Among them, a transgenic model expressing kRAS develops liver tumors and
appears to be representative of those human HCCs activating Ras signaling, which account for up
to 50% of cases [205,206]. Transgenic expression of HBx in a TP53 mutant background induces HCC
in 44% of fish, whereas zebrafish expressing HCV core protein swiftly develop HCC when exposed
to carcinogens [207,208]. Up to 40% of human HCCs result from activating mutations in the gene
encoding for β-catenin (CTNNB1). The zebrafish model was used to prove that activated β-catenin
expression in a small subset of hepatocytes is sufficient to drive HCC initiation [209]. Zebrafish are
effective as disease models because of their high fecundity, low housing cost, and transparency, which
allows live imaging and is useful to explore mechanisms by which HBV and HCV induce HCC.
Moreover, large experimental sample sizes are allowed, allowing informative studies. Finally, small
molecules can be added directly to the zebrafish’s water, thus avoiding the gavage often required in
rodents. The disadvantages are mainly related to the low amounts of liver tissue available for different
assays and the lack of antibodies able to recognize zebrafish antigens.
15. Conclusions
Advances in tumor biology have led to the identification of new targets that hold promise for
ameliorating HCC patients’ outcome. Translation of novel treatments requires preclinical testing in
animal models mirroring human HCC. New approaches should be tested in specific models, identified
on the basis of molecular matching. A wide range of rodent models of HCC is now available. Most of
them were characterized from a molecular point of view, including miRNA aberrant expression.
Remarkably, the multitargeting function of miRNAs make it mandatory to define the molecular context
for each experimental purpose and to fully characterize each model not only for miRNA but also for
targets expression, at least as far as the oncogenic drivers are concerned. Indeed, targeted treatments
should be tested in models that are representative of specific HCC subgroups, in order to assess those
settings in which they are awaited to work at their best.
The restoration of miR-199a-3p and miR-26a levels as promising miRNA-based anticancer strategies
have been assayed in several HCC animal models by using different therapeutic approaches, such as
miRNA mimics or AAV particles. On the other side, the silencing of onco-miR-221 holds great promise
as a therapeutic option in the oncologic field. Indeed, miR-221 plays oncologic functions in almost
all solid malignancies, and its inhibition represents a possible common strategy for different cancer
types. Interestingly, the development of innovative strategies for the production of miRNA-modified
molecules with a nonimmunogenic backbone to increase the stability in body fluids, and the engineering
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of nanoparticles for enhanced miRNA delivery, are further steps toward the translation of preclinical
findings into the clinics.
Besides rodents, other models appear very interesting, such as, for example, zebrafish, which are
easier to house, but they are still rarely adopted for preclinical studies on HCC.
In conclusion, HCC models focused to miRNA studies should be chosen based on a profound
knowledge of the molecular context, with specific reference to expression assessment of oncogenic
drivers targeted by the miRNA of interest. In addition, in HCC several deregulated miRNAs share
common targets. Several oncogenic drivers are targeted by multiple deregulated miRNAs. This opens
the door to combined approaches aimed at modulation of panels of critical miRNAs, instead of
single miRNA. These combined approaches might help to control the well-known feedback loops
elicited by miRNAs’ enforced expression or inhibition, which may impair the success of miRNAs
manipulation. Indeed, the complex action miRNAs, the modulation of many targets, sometimes
with opposite functions, should always be kept in mind, in order to avoid unexpected results in the
translational steps.
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TG transgenic
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c-Myc avian myelocytomatosis virus oncogene cellular homolog
mTOR mammalian target of rapamycin
Ras Kirsten rat sarcoma viral oncogene homolog
PI3K phosphoinositide 3-kinase
AFP alpha-fetoprotein
Igf2 insulin-like growth factor 2
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